Modus Therapeutics to Present at Biotech Showcase 2018 in San Francisco
STOCKHOLM, SWEDEN – 5 January, 2018. Modus Therapeutics AB, a company focused on innovative treatments for patients with sickle cell disease (SCD), today announces that CEO Ellen K. Donnelly will present at the 10th Annual Biotech Showcase held in San Francisco (CA, United States) from January 8 – 10, 2018.
Presentation details are as follows:
Date: Tuesday, 9 January 2018
Time: 4:30 pm PT
Location: Franciscan C room at the Hilton San Francisco Union Square Hotel
The presentation will provide an overview of Modus’ strategy and the clinical development plan for sevuparin, a novel anti-adhesive drug with the potential to prevent painful vaso-occlusive crises (VOC) in SCD patients through freeing blood vessel blockages and restoring blood flow. There are currently no pharmaceutical products that target the underlying cause of VOC.
The Company is conducting a Phase II study in Europe and the Middle East evaluating sevuparin in the treatment of SCD (NCT02515838), for which patient enrolment continues and results are expected in 2018.
Ellen K. Donnelly, Chief Executive of Modus Therapeutics, commented: “We are delighted to present at this year’s Biotech Showcase, where we will provide a strategic overview of the development of sevuparin for the treatment of SCD and its potential benefits, not only in reducing the pain and severity of the disease, but also in allowing self-administration and shortening hospital stay.”
Biotech Showcase™ is an investor and networking conference providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
For further information, please contact:
Ellen K Donnelly, CEO, Modus Therapeutics:
Tel: +46 70 246 7554
David Dible/ Pip Batty, Citigate Dewe Rogerson
Tel: +44 20 7638 9571